Citigroup Maintains Buy on GILD (Gilead Sciences, Inc.) March 2026

Citigroup maintained a Buy rating on Gilead Sciences, Inc. (GILD) on March 06, 2026 and left the recommendation unchanged. The GILD analyst rating appears alongside market commentary noting accelerating weekly Yeztugo scripts, a point highlighted in media coverage. StreetInsider reported that BofA also reiterated a Buy in related coverage, though no new price target was published. The firm-level action and sector notes matter for investors watching Gilead’s infectious disease and oncology revenue streams and near-term sentiment.

GILD analyst rating details and timing

Citigroup’s action on March 06, 2026 was recorded as a maintained Buy rating at 08:25 AM. The entry lists the analyst firm as Citigroup and shows a small intraday price move of -0.24% ($-0.34) attached to the note. No explicit price target was disclosed in the Citigroup record for this update.

News context: BofA note and Yeztugo script growth

StreetInsider published a note headlined that BofA Securities reiterated a Buy on Gilead as weekly Yeztugo scripts accelerate. That coverage underscores a commercial growth data point traders watch closely. The StreetInsider item provides third-party context but does not replace the Citigroup maintained rating recorded in our update source. Additional company profile and analyst summaries are available on Seeking Alpha for background source.

What the GILD analyst rating means for investors

A maintained Buy means the analyst expects outperformance versus the benchmark, not an immediate catalyst. Investors should read this as continued confidence in Gilead’s product mix and near-term commercial traction. The lack of a new price target signals the analyst sees ongoing progress but no fresh valuation trigger today.

Historical analyst coverage and pattern

Gilead has had steady coverage from major firms over several years, alternating Buy and Hold views as pipeline data and drug launches evolve. Analysts have historically reacted to product launches, HIV and HCV legacy revenues, and newer assets such as Yeztugo. The maintained Buy fits a pattern of measured optimism tied to commercial uptake rather than abrupt ratings swings.

Stock performance, market cap, and Meyka grade

Gilead’s market cap stands at $178,714,823,200 and the recent note coincided with a minor price change of -0.24% ($-0.34). Meyka AI rates GILD with a grade of B+. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus.

Near-term catalysts and what to watch next

Investors should monitor weekly Yeztugo scripts, upcoming earnings, and pipeline readouts to test the maintained Buy thesis. Watch for any published price targets from Citigroup or other firms and for follow-up notes that quantify revenue trajectory. A shift in scripts or a revised guidance will likely prompt fresh GILD analyst rating moves.

Final Thoughts

The core takeaway is simple: on March 06, 2026 Citigroup kept a Buy on Gilead Sciences, Inc. (GILD), and media outlets noted accelerating Yeztugo prescriptions that support continued optimism. The update included no new price target, so investors should treat this as confirmation of existing conviction rather than a fresh valuation call. Gilead’s $178,714,823,200 market cap and stable coverage profile make it a focus for income and growth-minded investors who track drug launches and script trends. Meyka AI rates GILD with a grade of B+. That grade blends S&P 500 comparison, sector performance, financial growth, key metrics, and analyst consensus. Use the maintained Buy as one input among earnings, commercial data, and pipeline news. For active traders, watch weekly Yeztugo script reports and any forthcoming analyst notes that add price targets or change rating stances. Meyka AI-powered market analysis platform will track subsequent coverage in real time.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Analyst ratings are opinions and not guarantees of future performance. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.